IMPACT OF LETERMOVIR PROPHYLAXIS ON CYTOMEGALOVIRUS EVENTS AND RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR AML AND MDS (EBMT 2026) - Mar 14, 2026 - Abstract #B132; Pres time: Mar 24, 2026; 06:00 PM - 07:00 PM; Location: VELAZQUEZ; " We conducted a single-center retrospective study of adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who underwent first allo-HSCT with uniform fludarabine/busulfan-based conditioning between January 2016 and September 2024. Letermovir prophylaxis fundamentally reshapes the post-transplant CMV landscape, uncoupling ECMVR from routine clinical observation. Although letermovir use was associated with higher unadjusted relapse incidence, this association disappeared after accounting for ECMVR and transplant-related covariates, while ECMVR itself remained independently protective against relapse. These data suggest that letermovir does not promote relapse but rather may obscure a CMV-associated immune signal linked to graft-versus-leukemia effects."
Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Transplantation
|
|
Sin Young Park1; Dong Hyun Kim1; Hyunsoo Cho1,2,3; Ja Min Byun1,2,3; Youngil Koh1,2,3; Dong-Yeop Shin1,2,3; Inho Kim1,2,3; Jun Shik Hong1,2,3
|